Clinical Trials on Cholestasis, Extrahepatic

Total 688 results

Xijing Hospital of Digestive Diseases

Recruiting

Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
Nanjing Chia-tai Tianqing Pharmaceutical

Recruiting

Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
Zydus Therapeutics Inc.

Active, not recruiting

Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis (EPICS-III)

Primary Biliary Cholangitis

United States, Argentina, Iceland, Turkey
Intercept Pharmaceuticals

Active, not recruiting

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

Primary Biliary Cholangitis

United States
Gannex Pharma Co., Ltd.

Completed

Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
Mayo Clinic

Active, not recruiting

Genetic Epidemiology of Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

United States
Cascade Pharmaceuticals, Inc

Completed

Study of [14C]CS0159 in China Healthy Subjects

Primary Biliary Cholangitis

China
CymaBay Therapeutics, Inc.

Completed

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, France, Korea, Republic of, Denmark, Australia, Italy, United Kingdom, Belgium, Canada, Russian Federation, Romania, Germany, Hungary, Mexico, Turkey, Argentina, Austria, Chile, Czechia, Greece, Israel, New Zealand and more
Cascade Pharmaceuticals, Inc

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects

Primary Biliary Cholangitis

China
Intercept Pharmaceuticals

Completed

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Arena Pharmaceuticals

Terminated

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States, Australia, New Zealand
Intercept Pharmaceuticals

Completed

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis (POISE)

Primary Biliary Cirrhosis

United States, Spain, United Kingdom, Austria, Netherlands, Australia, Italy, Germany, Poland, Sweden, France, Canada, Belgium
Gilead Sciences

Terminated

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis (PBC-Phase 2)

Primary Biliary Cholangitis

United States, Canada, Austria, United Kingdom
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

China
Biocad

Terminated

Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis

Liver Cirrhosis, Biliary

Russian Federation
Mirum Pharmaceuticals, Inc.

Withdrawn

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis (CASCADE)

Primary Biliary Cirrhosis

United States, United Kingdom
SAMEY
Axonal-Biostatem

Unknown

A Post-Authorisation Non-Interventional Observational of Patients in France With Primary Biliary Cholangitis Treated With Obeticholic Acid in Real Life (OCARELIFE)

Primary Biliary Cholangitis

France
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia, New Zealand
Xijing Hospital of Digestive Diseases

Unknown

Fuzhenghuayu in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

China
Fast Forward Pharmaceuticals

Unknown

Pilot Study of FFP104 Dose Escalation in PBC Subjects

Primary Biliary Cirrhosis

Netherlands, United Kingdom
Instituto Nacional de Ciencias Medicas y Nutricion...

Completed

High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

Mexico
Light Chain Bioscience - Novimmune SA

Terminated

Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody (PIANO)

Primary Biliary Cirrhosis

Italy, United Kingdom
Mayo Clinic
UCB Pharma

Completed

Moexipril for Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis

Liver Cirrhosis, Biliary

United States, Puerto Rico
Beijing Trendful Kangjian Medical Information Consulting...

Completed

Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC

Cholestatic Liver Disease

China
Intercept Pharmaceuticals

Terminated

Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT)

Liver Cirrhosis, Biliary

United States, Spain, Korea, Republic of, Australia, Finland, Israel, Lithuania, United Kingdom, Belgium, Netherlands, Estonia, Brazil, Italy, Serbia, Sweden, Argentina, Austria, Canada, Chile, Denmark, France, Germany, Hong Kong, Hun... and more
Intercept Pharmaceuticals

Terminated

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

Liver Cirrhosis, Biliary

United States, Argentina, Spain, Belgium, Germany, Canada, Australia, Estonia, Brazil, Hungary, Italy, Lithuania
Assistance Publique - Hôpitaux de Paris

Terminated

Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION (CHOLANGIOSIR)

Cholestasis, Progressive Familial Intrahepatic 3

France
Mayo Clinic
American College of Gastroenterology

Completed

Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC) (PBC)

Fatigue | Primary Biliary Cirrhosis

United States
University of Alberta
GlaxoSmithKline; Axcan Pharma

Completed

Study of Combivir for Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Canada, United Kingdom
Ipsen

Not yet recruiting

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE)

Primary Biliary Cholangitis
Xijing Hospital of Digestive Diseases

Recruiting

Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
University of Milano Bicocca
Intercept Pharmaceuticals; Laboratoires Mayoly Spindler

Recruiting

National Database on Primary Biliary Cholangitis (PBC322)

Primary Biliary Cholangitis

Italy
Fondazione Epatocentro Ticino

Recruiting

Swiss Primary Biliary Cholangitis Cohort Study

Liver Cirrhosis, Biliary

Switzerland
Xijing Hospital of Digestive Diseases

Recruiting

Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid

Primary Biliary Cirrhosis

China
Intercept Pharmaceuticals

Active, not recruiting

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Primary Biliary Cholangitis

Netherlands, United Kingdom, Korea, Republic of, Germany, Australia, Estonia, Belgium, France, Czechia, Croatia, Greece, Hungary, Israel, Lithuania, Norway, Poland, Spain
COUR Pharmaceutical Development Company, Inc.

Active, not recruiting

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States
Intercept Pharmaceuticals
Syneos Health; Global PBC Study Group; Target RWE; UK PBC Study Group

Withdrawn

A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients (HEROES-PBC)

Primary Biliary Cholangitis

United States
Yale University
American Liver Foundation

Suspended

Mindfulness - Based Intervention in the Treatment of Fatigue in Patients With Primary Biliary Cholangitis

Primary Biliary Cholangitis

United States
Novartis Pharmaceuticals

Completed

A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients

Primary Biliary Cholangitis

United States, Germany, Russian Federation, Canada, United Kingdom, Poland
Christopher Bowlus, MD
Bristol-Myers Squibb

Completed

Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

United States
Dr. Falk Pharma GmbH

Terminated

Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

France, Germany
West China Hospital

Completed

The Comparison About the Response of Ursodeoxycholic Acid in Primary Biliary Cholangitis Only and Primary Biliary Cholangitis With High Immune Globulin G or Aminotransferase at West China Hospital

Primary Biliary Cholangitis

China
EA Pharma Co., Ltd.

Terminated

Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid

Primary Biliary Cholangitis

Japan
University of California, Davis
Genentech, Inc.

Completed

Initial Study of Rituximab to Treat Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
George Brewer
FDA Office of Orphan Products Development

Completed

Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia
Janssen Research & Development, LLC

Completed

A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

Primary Biliary Cirrhosis

United States, Canada
University of Alberta
Canadian Institutes of Health Research (CIHR); Gilead Sciences; Abbott

Completed

Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis (HAART)

Primary Biliary Cirrhosis

Canada
Beijing 302 Hospital

Unknown

Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

China

Clinical Trials on Cholestasis, Extrahepatic

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations